Scholarlink

Background <p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a rare but potentially life-threatening hypersensitivity reaction characterized by skin rash, fever, lymphadenopathy, hematologic abnormalities, and organ involvement. Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is used to treat ovarian, fallopian tube, or primary peritoneal cancer. Although niraparib is associated with cutaneous toxicities, no severe cutaneous adverse reactions (SCARs) have been reported until now.</p> Case presentation <p>We present a case of DRESS syndrome in a 73-year-old woman with high-grade serous ovarian cancer treated with niraparib. After 20 days of therapy, she developed a widespread maculopapular rash. Despite discontinuation of niraparib and treatment with corticosteroids, she exhibited pruritus, facial edema, lymphadenopathy, eosinophilia, and impaired liver and renal function. A RegiSCAR score of 6 confirmed the diagnosis of DRESS. Patch testing to niraparib 1% in DMSO was positive when performed nine weeks after DRESS resolution.</p> Conclusions <p>This is the first reported case of DRESS by hypersensitivity due to niraparib. This case highlights the importance of recognizing DRESS as a potential adverse reaction to niraparib and the efficacy of early corticosteroid intervention. Further research is needed to understand and mitigate the risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) caused by niraparib: a novel antineoplastic agent

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月2日

查看全文
  • Irene Vázquez-Barrera,
  • Alba Juárez-Guerrero,
  • Cristina Cuevas-Bravo,
  • Patricia Rojas Perez-Ezquerra,
  • Blanca Noguerado-Mellado

摘要

Background

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a rare but potentially life-threatening hypersensitivity reaction characterized by skin rash, fever, lymphadenopathy, hematologic abnormalities, and organ involvement. Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is used to treat ovarian, fallopian tube, or primary peritoneal cancer. Although niraparib is associated with cutaneous toxicities, no severe cutaneous adverse reactions (SCARs) have been reported until now.

Case presentation

We present a case of DRESS syndrome in a 73-year-old woman with high-grade serous ovarian cancer treated with niraparib. After 20 days of therapy, she developed a widespread maculopapular rash. Despite discontinuation of niraparib and treatment with corticosteroids, she exhibited pruritus, facial edema, lymphadenopathy, eosinophilia, and impaired liver and renal function. A RegiSCAR score of 6 confirmed the diagnosis of DRESS. Patch testing to niraparib 1% in DMSO was positive when performed nine weeks after DRESS resolution.

Conclusions

This is the first reported case of DRESS by hypersensitivity due to niraparib. This case highlights the importance of recognizing DRESS as a potential adverse reaction to niraparib and the efficacy of early corticosteroid intervention. Further research is needed to understand and mitigate the risk.